Citigroup Maintains Buy on Evolent Health, Raises Price Target to $5.5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.
Citigroup analyst Daniel Grosslight maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $4 to $5.5.